Abstract: An absorbable iron-based alloy implantable medical device, including an iron-based alloy substrate and a degradable polymer coating and a zinc-containing protector which are arranged on the surface of the iron-based alloy substrate. The zinc-containing protector is selected from zinc and/or a zinc alloy, or a mixture of zinc and/or a zinc alloy and a degradable binder. The weight percentage of the zinc and/or zinc alloy in the mixture is greater than or equal to 20% and less than 100%. The zinc-containing protector is capable of delaying the corrosion of the iron-based alloy substrate during the early stage of implantation, such that the iron-based alloy substrate essentially avoids corrosion during the early stage of implantation and the clinical mechanical property requirements for the device in the early stage of implantation can be satisfied.

Abstract: An implantable drug-loaded device, including a zinc-containing matrix and an active drug layer attached to the zinc-containing matrix. In the zinc-containing matrix per unit area, the content of an active drug is ? (?g·mm?2). The content of zinc corroded from the zinc-containing matrix per unit area in a guaranteed grade acetic acid aqueous solution at 8.3 vol % within unit time is p (?g·mm?2·min?1). The value of ? and the value of p satisfy the following relation: 0.1?15p+??3.5, where p is greater than or equal to 0.005 and less than or equal to 0.14. The zinc release rate of the implantable drug-loaded device is matched with the content of the active drug, so after the implantable drug-loaded device is implanted into a body, the zinc and the drug work synergistically to effectively inhibit smooth muscle cell proliferation, and cannot kill cells and cause necrosis in tissues.

Abstract: An implantable apparatus, including at least one corrodible zinc-containing portion, where a content range of zinc in the at least one zinc-containing portion is [30, 50) wt. % and zinc in the zinc-containing portion is an amorphous structure, or a content range of zinc in the at least one zinc-containing portion is [50, 70] wt. %, and a microscopic structure of zinc in the zinc-containing portion is at least one of an amorphous structure, a non-equiaxed structure, an ultrafine-grained structure, or an equiaxed structure with a grain size number of 7 to 14, or a content range of zinc in the at least one zinc-containing portion is (70, 100] wt. % and a microscopic structure of zinc in the zinc-containing portion is at least one of a non-equiaxed structure, an ultrafine-grained structure, or an equiaxed structure with a grain size number of 7 to 14.

Abstract: An absorbable iron-based alloy implantable medical device, including an iron-based alloy substrate and a degradable polymer coating and a zinc-containing protector which are arranged on the surface of the iron-based alloy substrate. The zinc-containing protector is selected from zinc and/or a zinc alloy, or a mixture of zinc and/or a zinc alloy and a degradable binder. The weight percentage of the zinc and/or zinc alloy in the mixture is greater than or equal to 20% and less than 100%. The zinc-containing protector is capable of delaying the corrosion of the iron-based alloy substrate during the early stage of implantation, such that the iron-based alloy substrate essentially avoids corrosion during the early stage of implantation and the clinical mechanical property requirements for the device in the early stage of implantation can be satisfied.

Abstract: An intravascular stent (100, 200, 300) comprises a framework with openings and at least one radiopaque structure (103, 201, 301). Each radiopaque structure (103, 201, 301) comprises fixed bodies and radiopaque markers (105, 208, 307) filled in the fixed bodies. The fixed bodies are connected with the framework, and are at least partially disposed in the openings. The envelope enclosed area of all the radiopaque markers (105, 208, 307) in each radiopaque structure (103, 201, 301) is less than or equal to 2 mm2, and a sum of effective areas of all the radiopaque markers (105, 208, 307) in each radiopaque structure (103, 201, 301) is greater than or equal to 0.15 mm2, and a ratio of said sum of effective areas to said envelope enclosed area is greater than or equal to 1:5. The radiopaque structure (103, 201, 301) has a desirable visibility, and does not substantially affect the crimped diameter of the intravascular stent (100, 200, 300).